Cleavage of the alpha-methene bridge of heme by membrane-bound heme oxygenase yields equimolar amounts of biliverdin, carbon monoxide, and reduced iron. Biliverdin is catalyzed by biliverdin reductase to bilirubin. The process occurs in all nucleated cells except mature anucleated red blood cells. Neonates in whom bilirubin production is increased tend to have higher bilirubin concentrations, and excessive bilirubin production or impairment of elimination causes dramatic deviations from the hourspecific nomogram that can be seen as "jumping" percentile tracks early in the postnatal period or later in the first week after birth. After formation, bilirubin diffuses into the circulation. In the absence of conjugates, the total bilirubin concentration in plasma is the sum of bilirubin bound to albumin plus a minimal amount of free bilirubin. Bilirubin is excreted more slowly in newborns than in adults. Although no clinical tests can measure bilirubin uptake and conjugation by the liver, an elevated hour-specific total bilirubin value when bilirubin production is normal or decreasing is a sign of impaired or abnormally delayed bilirubin excretion. The accuracy and precision of clinical laboratory total bilirubin measurements are a concern, and studies are underway to assess whether measurements of free bilirubin, the bilirubin-binding constant, the bilirubin:albumin ratio, or albumin binding capacity might improve the ability to identify infants at greater risk for bilirubin-induced neuroinjury rather than simply those at greater risk for having a higher bilirubin concentration.
Introduction
Neonatal jaundice is one of the most common clinical phenomena encountered in newborns. It is caused by the accumulation in the skin and sclerae of the yellow-orange pigment bilirubin (4Z,15Z-bilirubin-IX-alpha), the predominant isomer that is formed naturally from the degradation of heme in mammals. Hyperbilirubinemia causes jaundice and, in the newborn, reflects the relative lack of bilirubin glucuronidation by the immature liver during the transitional period after birth. With increasing conjugation in the maturing infant (or in cholestatic states), the blood contains not only unconjugated bilirubin bound to albumin and a small amount of free bilirubin, but also bilirubin glucuronides and biliproteins (delta-bilirubin), the latter of which results from the covalent bonding between conjugated bilirubin and albumin. (1) Because hyperbilirubinemia in the newborn is largely due to unconjugated bilirubin, this type of jaundice is practically uncomplicated in most infants in the first several days after birth. An elevated "direct" fraction of bilirubin, however, signals the need for an expanded differential diagnosis and other diagnostic tests. Thus, cholestatic jaundice of the newborn, although it can be seen in the context of hemolysis and phototherapy, is beyond the scope of this article.
Bilirubin Production
The source of bilirubin is singular, involving a phylogenetically ancient enzyme, heme oxygenase (HO), which initiates the first of a two-step heme (ferriprotoporphyrin IX) degradation process in mammals. (2) The process is nearly ubiquitous, occurring in all nucleated cells except mature anucleated red blood cells (RBCs), which lack this enzymatic system for degrading heme. The reticuloendothelial system, in particular the spleen, is important in degrading heme from hemoglobin-containing, senescing RBCs. Thus, continuous culling of aged RBCs by the spleen is a major contributor to the production of bilirubin in the body under normal conditions. In fact, approximately 80% of heme is derived from this source. The remainder is derived from the processes of ineffective erythropoiesis and the turnover of nonhemoglobin hemoproteins (eg, myoglobin, catalase, nitric oxide synthase, peroxidases, and cytochromes).
Isotopic labeling studies have aided in our understanding of the sources of heme that eventually yield bilirubin. Two pools of 14 C-labeled bilirubin (an "earlylabeled" or "shunt" bilirubin pool and a "late-labeled" pool) appear when labeled heme precursors ( 14 C-labeled glycine-and delta-amino-levulinic acid) are administered to animals. (3) The early-labeled pool is produced from the turnover of nonerythropoietic heme precursors, hemoprotein turnover, and ineffective erythropoiesis. The late-labeled pool appears when RBCs containing labeled heme become senescent and are degraded.
The schematized results in Figure 1 were obtained using fetal and adult RBCs, which have shorter and longer life spans, respectively, in various animal models. Although these two pools may differ quantitatively in the various animal models compared with humans, because of the differences in the relative life spans of the fetal and adult RBCs in the various species, qualitatively the human circumstance is likely to be comparable because human fetal RBCs also have a shorter life span (approximately 70 d) compared with human adult RBCs (approximately 120 d).
The concentration of the two well-described HO isozymes, HO-1 and HO-2, (4) varies between tissues. For example, HO-1 predominates in spleen and HO-2 predominates in the brain. (5) HO-2 is considered the constitutive (or "housekeeping") enzyme; it is developmentally regulated, and its expression appears to be influenced only by steroids. In contrast, HO-1 is inducible by its substrate heme and various other nonheme substances and stress conditions, (5) reflecting a very complex set of biologic roles. A putative isoenzyme, HO-3, also has been reported as largely homologous with HO-2, but with uncertain activity and an unknown role. (6) Although the role of HO as the initial and ratelimiting step in the production of bilirubin is relevant to understanding neonatal jaundice, it is important to recognize that the biology of HO is old and probably essential to much life on this planet because of the physical and chemical exigencies of light, oxygen, and plentiful iron. In particular, the role of HO in the evolution of the human species invites intriguing speculation about the influences of pathogens on the human genome, such as the protozoan Plasmodium falciparum, which causes malaria. (7) Infection with this agent certainly would involve increased expression of HO-1 in response to the heme loads caused by hemolysis. Although the role in the actual pathogenesis of the infection remains speculative, the fact that there is great variation in HO-1 expression in humans related to (GT) n polymorphism of the HO-1 gene promoter, with long (GT) n repeats influencing basal activity or inducibility of the HO-1 gene promoter, and, in particular, promoter activity decreasing with increasing (GT) repeat numbers, is intriguing in this context. (8)(9) Perhaps host differences in HO-1 expression contribute to the individual vulnerability to certain infections, such as malaria, (7) and the predilection for pregnancy disorders. (10) Moreover, HO-1 expression may be generally important in antioxidant defense, and it may have roles in other conditions that involve oxidant stress, such as hypoxia, heat shock, and disorders of aging, including cardiovascular, neurologic, and renal diseases. (7) Cleavage of the alpha-methene bridge of heme by membrane-bound HO is the initiating event in heme catabolism (Fig. 2) and ultimately yields equimolar amounts of green-colored biliverdin, carbon monoxide (CO), and reduced iron (Fe 2ϩ ). (2) The reaction mechanism is complex and requires three molecules of oxygen and at least seven electrons donated from the nicotinamide adenine dinucleotide phosphate (NADPH)-cytochrome-P-450 reductase system. The actual cleavage of the tetrapyrrole macrocycle containing iron is autocatalytic in the sense that the bound heme serves both as a prosthetic group and a substrate. Biliverdin is reduced rapidly in the cytoplasm, catalyzed by biliverdin reductase to bilirubin, thus linking CO production and bilirubin production. (11) The stoichiometry of the reaction presents the opportunity to use CO production as an index of biliverdin/ bilirubin production. CO, an important signaling molecule in its own right, (12) has the potential for interacting with other heme-containing compounds, including many important enzymes. CO diffuses easily into blood, binding with the hemoglobin in RBCs to form carboxyhemoglobin (COHb). In the lung, the high concentration of oxygen displaces CO from COHb, allowing it to diffuse into the alveoli and be exhaled continuously in breath. The reduced iron is rendered harmless by binding to ferritin, the major iron storage protein. On a body weight basis, a newborn produces about two to three times as much bilirubin as an adult, thus setting the stage for neonatal jaundice because the capacity to eliminate the pigment is temporarily diminished after birth compared with an adult. (13) In the human newborn, many pathologic conditions increase bilirubin production, and neonates in whom bilirubin production is increased are inclined to have higher bilirubin concentrations, depending on their capacity to eliminate the pigment. Even the hour-specific nomogram (see the accompanying article in this issue by Keren and Bhutani) is informed by bilirubin production, with infants tracking in the high quartiles having, on the average, higher bilirubin production because all infants have relatively impaired elimination. (14) Excessive bilirubin production or impairment of elimination causes dramatic deviations from the nomogram that can be observed easily as "jumping" percentile tracks early in the postnatal period (typically related to increased bilirubin production) or later in the first week after birth (typically related to impaired elimination) (Fig. 3) . Excessive bilirubin production has many causes, but one of the more serious and relatively common ones is maternofetal blood group incompatibility, with a positive Coombs test contributing to increased RBC degradation and bilirubin production.
Although the hour-specific bilirubin nomogram is a convenient method for early detection of babies who have increased bilirubin production (because such infants "jump" to higher percentile tracks), a more specific method for detecting increased bilirubin production is to measure CO in exhaled air. (15)(16) Neonates who have abnormally high rates of bilirubin production have been shown to have abnormally high CO excretion rates or end-tidal breath CO values, corrected for ambient CO.
Increased bilirubin production sets the stage not only for transitional bilirubin physiology and pathophysiology, but increases the bilirubin load that must distribute into a variety of body compartments, including the cir- culation and body tissues, based on biochemical principles and a variety of other influences on this biochemistry. Nonetheless, the more bilirubin that is produced, the more bilirubin that potentially can distribute within the body of an individual and the more risk for a toxic reaction, depending on the vulnerability of the exposed tissues. Bilirubin toxicity also is beyond the scope of this article, but must be understood as a potential adverse effect of the pathologic accumulation of bilirubin that exceeds the very much lower concentrations in cells, tissues, or circulation and contributes to antioxidant defense. (17)(18)(19)
Bilirubin Transport
After bilirubin is formed, it diffuses into the circulation, where it binds reversibly to albumin (bilirubin:albumin). The equilibrium concentration of the nonalbuminbound or "free" bilirubin is about three orders of magnitude less than the bilirubin:albumin concentration. In the absence of conjugates, the total bilirubin concentration in plasma is the sum of bilirubin:albumin plus a minimal amount of free bilirubin concentrations. Although the bilirubin:albumin complex may be thought of as a reservoir of bilirubin that potentially can leave the circulation and enter tissues, free bilirubin governs the speed with which bilirubin in circulation actually enters the tissues and the steady-state distribution of bilirubin between the circulation and the tissues. Because albumin concentrations and bilirubin-albumin binding constants vary considerably among babies, the free bilirubin at any given bilirubin concentration in circulation can vary greatly, making it difficult to assess bilirubin movement into tissues. (20)(21)(22)(23)(24) The bilirubin concentration in circulation, measured as serum or plasma total bilirubin, is the conventional clinical laboratory measurement on which the treatment of newborn jaundice is based because most newborns have nominal concentrations of direct-reacting bilirubin, which includes all bilirubin moieties except bilirubin bound to albumin and free bilirubin. However, measuring free bilirubin in addition to total bilirubin has the potential to provide useful information about the relative amount of bilirubin that is outside the circulation in tissues, in particular, the brain. Importantly, "low" total bilirubin concentrations are not always due to lower-than-normal concentrations of bilirubin in the body (that is, the miscible bilirubin pool, which is the bilirubin in circulation plus the bilirubin in tissue). Rather, they could be due to weaker-than-normal bilirubin-albumin binding, with a higher proportion of bilirubin residing outside the circulation in tissue, including the brain.
Measuring the free bilirubin in addition to the hourspecific total bilirubin and estimating bilirubin production using CO measurements can be helpful in understanding the risk faced by some babies because they have a large bilirubin load distributed in part outside the circulation. Thus, it is possible that some babies who have "low" total bilirubin values are at risk and others who have "high" total bilirubin values are not, depending on the load and distribution of that load. Routine measurement of free bilirubin is presently not available, but measurements of albumin and the total bilirubin: albumin ratio can assist in identifying newborns who may have compromised bilirubin transport. The total bilirubin/albumin molar ratio at which intervention is recommended increases with increasing gestational age, but in otherwise well term newborns, it should be below 0.8 (about 7 mg of bilirubin per gram of albumin).
Although the free bilirubin concentration determines the movement of bilirubin from the circulation into tissue, less is known about the in vivo variables that affect exposure of the brain to bilirubin, including the various transporters involved with pumping bilirubin out of the central nervous system. Other relevant factors include the intracellular metabolism of bilirubin (eg, bilirubin oxidase catalyzed oxidation of intracellular bilirubin to nontoxic biliverdin, colorless diazo-negative compounds, and monopyrrole propentdyopents). Because such factors are not accessible clinically, bilirubin toxicity is determined by clinical means, including physical examination (eg, lethargy, irritability, and opisthotonus), auditory brainstem response, and magnetic resonance imaging, which may show changes in the basal ganglia and hippocampus.
Bilirubin Excretion
Bilirubin is excreted more slowly in the newborn compared with the adult because of a transiently slower rate of hepatic uptake of free bilirubin from the blood and decreased concentrations of uridine diphosphoglucuronate glucuronosyltransferase (UGT), the enzyme that catalyzes conjugation of bilirubin with glucuronic acid to form water-soluble, nonneurotoxic bilirubin mono-and diglucuronides, which are required for bilirubin excretion. Although excretion can occur with monoglucuronides, diglucuronides facilitate bilirubin excretion further. As free bilirubin uptake and conjugation improve over the first 2 weeks after birth, increasing amounts of conjugated bilirubin enter the bile ducts and are excreted with the bile into the intestinal tract. In the distal segments of the intestinal tract, primarily in the colon, bacterial flora progressively hydrogenate bilirubin to urobilinogen, urobilins, and stercobilins. (25) Bilirubin oxidase is also present in the liver and intestinal mucosa, but whether bilirubin oxidation by bilirubin oxidase contributes significantly to bilirubin excretion is unknown.
Bilirubin monoglucuronide and bilirubin diglucuronide may be deconjugated in the gut by betaglucuronidase to bilirubin, which then is reabsorbed into the bloodstream. This process, known as the "enterohepatic bilirubin circulation," is common in newborns and is affected by breastfeeding and infant nutritional status. The meconium accumulating in the gut in utero also contains about 100 to 200 mg of bilirubin per 100 g of meconium at birth, of which 50% or more is unconjugated. (25) Thus, the miscible pool of bilirubin is affected not only by the relative rates of bilirubin production and removal from the circulation by the liver, but also by the rates of enterohepatic circulation and meconium excretion.
No clinical tests are available to measure bilirubin uptake and conjugation by the liver, but an elevated hour-specific total bilirubin value when bilirubin production is normal or even decreasing, as it should be after birth, is a sign of abnormally delayed bilirubin excretion. Although it is tempting to ascribe abnormally high hourspecific total bilirubin in the presence of a normal bilirubin production rate to impaired excretion or a normal total bilirubin in the presence of increased bilirubin production to enhanced bilirubin excretion, the effect of bilirubin-albumin binding on the total bilirubin should not be overlooked. For example, an abnormally high hour-specific bilirubin might occur when both bilirubin production and excretion are normal if bilirubin-albumin binding is very strong.
Two genetic conditions (Crigler-Najjar disease and Gilbert syndrome) are associated with abnormal bilirubin excretion, (26)(27)(28)(29) Clearly, the interaction of genes that impede bilirubin elimination from the body combined with any factors that increase bilirubin production creates the most dangerous circumstance for the neonate. Some gene interactions present serious challenges, such as the combined presence of glucose-6-phosphate dehydrogenase deficiency and Gilbert syndrome. (32)(37)(38) Other genetic variants can affect bilirubin excretion and are less likely to complicate the neonatal syndrome of indirect-reacting hyperbilirubinemia, but still are factors in the overall excretion of bilirubin. Such deficiencies include the canalicular multispecific organic anion transporter (cMOAT), also known as the multidrug resistance-associated protein 2 (MRP-2), which is associated with cholestasis in the Dubin-Johnson syndrome. (39) 
Measurement of Bilirubin
Total bilirubin traditionally was measured in serum, but it now is measured more commonly in plasma because most blood samples are obtained and centrifuged in tubes containing anticoagulants (eg, heparin, EDTA, or oxalate). (40) In addition, gels often are used to separate the serum or plasma from the RBCs and buffy coat, but the concentrations of bilirubin and its derivatives do not appear to be affected by the type of liquid matrix. For the sake of procedural and analytical accuracy, however, the proper matrix always should be identified.
More than a century ago, Ehrlich (41) discovered that bilirubin reacts with diazotized p-nitrobenzoic acid to form ruby-colored azo-bilirubin. Van den Bergh (42) studied this reaction further and developed it into a clinical assay still used today that allows identification and quantitation of the unconjugated (indirect) and conjugated (direct) bilirubin fractions (Table) .
The traditional method involves direct and indirect reactions with the diazo reagent, yielding colored bilirubin derivatives, which can be quantitated spectrophotometrically. Conjugated bilirubin (mono-and diglucuronides) and delta-bilirubin react directly with the diazo reagent (the so-called "direct"-reacting bilirubin). When an accelerant, such as caffeine or DMSO, is added to the in vitro diazo reaction mixture, unconjugated bilirubin (bilirubin:albumin and unbound bilirubin) is energized to react with the diazo reagent as well to form similar colored products (the so-called "indirect" reaction bilirubin). Thus, "indirect" bilirubin concentrations are derived from the total bilirubin concentration minus the direct bilirubin concentration. Total bilirubin is the sum of all bilirubin derivatives in a sample.
Direct spectrophotometry, fluorimetry, and highpressure liquid chromatography (HPLC) also are used to measure plasma bilirubin, its isomers, and derivatives. Although HPLC has proven to be a powerful technique for demonstrating and quantifying the various species of bilirubin present, it is not suitable for routine clinical use.
The accuracy and precision of clinical laboratory total bilirubin measurements are a continuing concern. Several groups have studied interlaboratory variability of total bilirubin measurements made with automated clinical analyzers using artificial sera containing bilirubin and have found room for improvement with better standardization. (43)(44)(45) Appropriate clinical intervention should be based only on accurate bilirubin fraction measurements, but this is not always the case at present. (45) Plasma (and serum) also may contain various photoproducts of bilirubin and glucuronides, which may interfere with some or all of the methods used to measure bilirubin fractions. (46) The relative proportions of these products are age-and subject-dependent. In addition, the administration of drugs, (47) nutrients (human milk), and treatments, such as phototherapy or exchange transfusion, may affect the relative concentrations of bilirubin compounds in circulation and tissues unpredictably. (46) Several studies suggest that measuring free bilirubin would be useful in assessing the jaundiced newborn. Studies are underway to assess whether measurements of free bilirubin, the bilirubin-binding constant, the bilirubin:albumin ratio, or albumin binding capacity might improve the ability to identify individuals who are at greater risk for bilirubin-mediated neuroinjury rather than simply at greater risk for having a higher bilirubin concentration, which is what the hour-specific total bilirubin nomogram does. (14) However, the relationship between bilirubin values and bilirubin toxicity is variable and influenced by other factors, such as binding of bilirubin to albumin. Unbound (or "free") bilirubin is more likely to cross the blood-brain barrier and cause brain injury. Most bilirubin normally is bound to albumin, resulting in low concentrations of unbound bilirubin. For patients who have high bilirubin concentrations, the capacity of albumin to bind bilirubin is exceeded, leading to higher concentrations of unbound bilirubin. The ratio of bilirubin to albumin (B/A) can be used as an approximate surrogate for unbound bilirubin. B/A ratio (Ն6.8) is used only in conjunction with measurements of bilirubin to determine whether an exchange transfusion should be initiated, as outlined in the 2004 American Academy of Pediatrics guideline, according to the infant's age and risk factors. (53) Preterm and sick infants often have decreased serum albumin concentrations and a reduced binding capacity, resulting in a higher proportion of unbound bilirubin for a given bilirubin value compared with healthy term infants. As a result, in these patients, a lower B/A ratio or bilirubin threshold is used to initiate therapy. Drugs such as sulfisoxazole, moxalactam, and ceftriaxone can displace bilirubin from albumin and increase the risk of bilirubin toxicity. Acidosis increases movement of bilirubin into tissues, including the brain and, thus, can contribute to the development of bilirubin-induced brain injury.
Although bilirubin can be measured in other materials (eg, meconium, bile, stool, urine, and cerebrospinal fluid) and could provide additional clinical information, how such information might be used currently is unknown.
Less than 2% of the miscible bilirubin pool is contained in the skin of the congenitally jaundiced Gunn rat. (54) The percentage of the miscible pool in the skin of the jaundiced human newborn is probably similar. Regardless, transcutaneous bilirubin measurements have been reported by many investigators to correlate with total bilirubin concentrations in plasma, even in pigmented newborns. (55) The noninvasive nature of the technology makes it easier to perform serial measurements than bilirubin measurements and monitor the rate at which the total bilirubin is changing in an hourspecific manner over time. The measurement of yelloworange color in the skin is, at best, a surrogate for total bilirubin in circulation. Although it may be technically possible using optical technology to measure the latter, current technology provides only an index of total bilirubin and should be used as an indication for appropriate blood sampling and testing.
Riskin and associates (56) (57) suggested that the visual assessment of jaundice by an experienced clinician may be reasonably reliable and may diminish the need for universal blood sampling. However, it is impossible to standardize visual assessments for the many variables encountered, such as lighting, skin color, color perception, clinical experience, and training, and this approach should be used with extreme caution. (58)(59) The bottom line is that visual inspection is inadequate for estimating the total bilirubin in circulation once a child is jaundiced from head to toe.
Conclusion
Bilirubin is not only a waste product, but also a versatile molecule that has an essential role in cellular metabolism. It is one product of a catabolic pathway that is essential for life on this planet. Although variations in HO-1 expression occur, it is probable that mammalian life as well as many other forms of life on this planet, including plant life, would not be possible without such an enzymatic system, although it may come in different forms. Without some mechanism to deal with oxygen, light, and iron, life would literally "burn out." Thus, bilirubin is an important molecule to measure in living things, including newborn babies. Its measurement is not trivial, and further improvements in measurement are required. More importantly, however, is the understanding of the beneficial effect of bilirubin as an antioxidant as well as its toxic effects. The latter are known to occur, but the mechanisms involved are still being investigated. Any strategy to prevent such bilirubin-related injury must begin with a sound understanding of bilirubin physiology and clinical chemistry. Understanding the cellular biology of heme catabolism and defining the roles of this ancient and elegant set of reactions in other developmental and pathological circumstances remains a scientific challenge.
